高级检索
当前位置: 首页 > 详情页

Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Universita degli Studi di Milano, Milan, Italy [2]Boston Children’s Hospital and Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA [3]Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy [4]Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China [5]NHC Key Laboratory of Organ Transplantation, Wuhan, China [6]Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China [7]Institute of Organ Transplantation,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China [8]Medicine, Al-Azhar University, Cairo, Egypt [9]Renal Division, Brigham and Women’s Hospital, Boston, MA
出处:
ISSN:

关键词: Diabetic kidney disease Diabetes Podocytes Glomerular cells

摘要:
Diabetic kidney disease (DKD) is the first cause of end-stage kidney disease in patients with diabetes and its prevalence is increasing worldwide. It encompasses histological alterations that mainly affect the glomerular filtration unit, which include thickening of the basement membrane, mesangial cell proliferation, endothelial alteration, and podocyte injury. These morphological abnormalities further result in a persistent increase of urinary albumin-to-creatinine ratio and in a reduction of the estimated glomerular filtration rate. Several molecular and cellular mechanisms have been recognized, up to date, as major players in mediating such clinical and histological features and many more are being under investigation. This review summarizes the most recent advances in understanding cell death mechanisms, intracellular signaling pathways and molecular effectors that play a role in the onset and progression of diabetic kidney damage. Some of those molecular and cellular mechanisms have been already successfully targeted in preclinical models of DKD and, in some cases, strategies have been tested in clinical trials. Finally, this report sheds light on the relevance of novel pathways that may become therapeutic targets for future applications in DKD.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 医学
小类 | 1 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 药学
JCR分区:
出版当年[2021]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者单位: [1]International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Universita degli Studi di Milano, Milan, Italy
通讯作者:
通讯机构: [1]International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Universita degli Studi di Milano, Milan, Italy [2]Boston Children’s Hospital and Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA [3]Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy [*1]International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Universita degli Studi di Milano,Milan, Italy
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:2 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)